yu tian

Dr. yu tian


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
YTyu tian
yu tian
YZYue Zheng
Yue Zheng
GTGuigen Teng
Guigen Teng
JLJunxia Li
Junxia Li
HWHuahong Wang
Huahong Wang
Microcirculatory disturbance is an important factor in the pathogenesis of Inflammatory Bowel Disease (IBD) but there have been few studies in this field. Confocal Laser Endomicroscopy (CLE) has been used over the last 10 years and has made it possible to explore the changes in microcirculation of the colonic mucosa. We retrospectively selected patients who underwent probe-based Confocal Laser Endomicroscopy (pCLE) between 2014 and 2016. There were 7 patients with ulcerative colitis (UC) in clinical remission and 7 healthy subjects included in this study; all the UC patients’ medical data were reviewed. For each patient, three segments of the colon were examined using pCLE including the ascending, transverse/descending and sigmoid colon. In each segment, the representative pCLE images of the three sites were selected for analysis. Four indicators, including Mean Vessel Diameter (MVD), Diameter Standard Deviation (DSD), Functional Capillary Density-long (FCDL) and Functional Capillary Density-area (FCDA), were measured with a specially designed detection software algorithm. The four indicators were compared between UC patients and healthy subjects. According to the different blood flow patterns, three types of distribution were established: the Around (A), Cobweb (C) and Deficiency (D) type. The relationships between the recurrence and blood flow patterns of UC patients were analyzed. MVD, DSD, FCDL and FCDA were 10.62 ± 0.56 μm, 2.23 ± 0.26, 0.030 ± 0.019 μm and 0.289 ± 0.030 for the healthy subjects and 11.06 ± 1.10 μm, 2.68 ± 0.29, 0.026 ± 0.005 μm and 0.272 ± 0.034 for the UC patients, respectively. Compared with healthy subjects, DSD was significantly increased and FCDA was significantly decreased (P < 0.01 for both). There was no difference in MVD and FCDL between UC patients and healthy subjects. The type A and type C blood flows were observed in healthy subjects (66.67 and 33.33%, respectively) while type C appears more in UC patients (71.3%) and type D blood flow could only be found in UC patients (14.29%) P < 0.01. UC patients who showed Type D blood flow had a shorter recurrence interval. Some local mucosal capillary density in UC patients was decreased, particularly in the inflammation-affected segment. The three mucosal blood flow patterns can be used as an indicator of mucosal healing.

28 May 2025 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SHSheng-Duo He
Sheng-Duo He
YTyu tian
yu tian
BACKGROUND Pyoderma gangrenosum (PG) is one of the most severe extra-intestinal manifestations of ulcerative colitis (UC). The treatment of refractory UC combined with PG is challenging, particularly for patients with schizophrenia (SCZ) with a long-term history of risperidone use, and there have been no successfully treated patients reported in the literature. CASE SUMMARY A 36-year-old woman attended the gastroenterological clinic due to intermittent symptoms of diarrhea and mucous bloody stools. Prior to the emergence of these symptoms, the patient had a history of SCZ for 3 years. She had been receiving long-term risperidone treatment and had stable mental symptoms. In April 2023, she was diagnosed with UC E3 moderate and began taking mesalazine 3 g/day. In March 2024, her intestinal symptoms recurred and approximately 2 months later, PG developed in both lower limbs. Previous treatments with adalimumab and steroids were ineffective for PG and UC, and simultaneously, the patient experienced headache, confusion, and severe sleep disturbances. After switching to upadacitinib (UPA) 45 mg/day, PG lesions showed complete healing and fecal calprotectin was < 10 μg/g after 7 weeks of treatment. Following approximately 12 weeks of UPA therapy, colonoscopy indicated that the patient had achieved mucosal healing. No adverse events occurred during UPA induction and maintenance therapy for 6 months with risperidone. CONCLUSION UPA treatment led to successful resolution of both intestinal and extra-intestinal manifestations in this patient with new-onset UC who had a history of SCZ. No adverse effects were observed with concurrent UPA and risperidone use.

3 April 2019 in Clinical Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
YTyu tian
yu tian
YZYue Zheng
Yue Zheng
JDJinpei Dong
Jinpei Dong
JZJixin Zhang
Jixin Zhang
HWHuahong Wang
Huahong Wang
Ulcerative colitis has hypercoagulable state and high risk of thrombosis; so mucosal disturbance of microcirculation may be mediate and amplify the inflammation of ulcerative colitis. A 56-year-old female patient was admitted in hospital for discontinuously mucous bloody stool for more than 1 year. Ulcerative colitis was determined after colonoscopy and pathologic examination. Mesalazine was effective during the year, but her symptoms recurred three times due to her bad compliance. One month before admission, the patient had severe recurrence after mesalazine withdrawal. At this time, the result of quantitative fluorescence PCR of colonic histic CMV-DNA was 1.6 × 104 copies/mL positive, CMV colitis was accompanied. After 4 weeks of ganciclovir and 6 weeks of mesalazine usage and nutrition support, the symptoms of diarrhea and abdominal cramp did not improve; stool frequency was more than twenty times a day. Probe-based confocal laser endomicroscopy revealed local microcirculation disturbance. Papaverine 90-mg slow drip for at least 10 h a day was added. The symptoms dramatically disappeared after 3 days of papaverine treatment. The patient had yellow mushy stool 2–3 times a day. Pathological findings showed diffuse submucosal hemorrhage and transparent thrombosis in capillaries. Treatment of microcirculatory disturbance in severe UC is a promising adjuvant therapy. Confocal laser endomicroscopy may be an effective method for microcirculation judgment.

1 May 2021 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
JDJinpei Dong
Jinpei Dong
YTyu tian
yu tian

18 October 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
YZYue Zheng
Yue Zheng
JZJixin Zhang
Jixin Zhang
JWJinwei Wang
Jinwei Wang
JLJunxia Li
Junxia Li
HWHuahong Wang
Huahong Wang
YTyu tian
yu tian
Background and Aim: The benefits of deep disease healing need evaluation by long‐term clinical research in different populations. Confocal laser endomicroscopy (CLE) is a superior method for evaluating deep disease healing. Methods: This prospective study enrolled ulcerative colitis (UC) patients in clinical remission who underwent colonoscopy, CLE, and histological assessment. Patients were monitored for relapse by patient‐reported outcomes and colonoscopy evaluation of mucosal healing. The ability of different methods of mucosal healing to predict long‐term disease recurrence was assessed using Kaplan–Meier estimation and Cox proportional hazard regression. Results: Forty‐two patients in clinical remission were assessed by colonoscopy. Those with Mayo endoscopic subscores (MES) ≤ 1 were enrolled. The 48‐month recurrence rates in present healing group, assessed by CLE (colonic barrier assessment and ENHANCE index) and by histological examination (Geboes scale), were 20.0%, 26.7%, and 11.1%, respectively, and were significantly lower than absent healing group ( P < 0.05). Univariate Cox proportional risk regression analysis in absent of healing disease, determined by the ENHANCE index and Geboes scale, indicated an increased risk of recurrent events, with hazard ratios (HR) of 3.87 (95% CI: 1.18, 12.62) and 8.20 (95% CI: 1.06, 63.30), respectively. Multivariate Cox proportional hazard regression analysis adjusted for the extent of inflammation (E3 or not) showed a significant difference only for the ENHANCE index, with an HR of 3.53 (95% CI: 1.03, 12.10), P = 0.045. Conclusions: Deep disease healing has a lower recurrence rate. The colonic barrier healing assessment, ENHANCE index, and histological Geboes scale have superior long‐term prognostic value for UC patients.

5 November 2026 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
SHShengduo He
Shengduo He
WZWei Zhang
Wei Zhang
YTYuling Tian
Yuling Tian
CGChaoyi Ge
Chaoyi Ge
GTGuigen Teng
Guigen Teng
YTyu tian
yu tian
Background: Upadacitinib (UPA), a selective Janus kinase 1 inhibitor, is approved for moderate-to-severe inflammatory bowel disease (IBD). JAK inhibitors affect lipid metabolism, but longitudinal real-world data on lipid changes during UPA therapy, and their relation to inflammatory activity, are scarce. Methods: In this single-center retrospective cohort study, patients with ulcerative colitis or Crohn’s disease treated with upadacitinib were followed for up to 2 years. Serial fasting lipid profiles and inflammatory markers (fecal calprotectin, C-reactive protein [CRP], high-sensitivity CRP) were collected at baseline, end of induction (weeks 8-12), 1 year, and 2 years. Lipid trajectories were analyzed with linear mixed-effects models; paired changes were compared with paired t-tests. Results: Among 159 patients (mean age 43.3 ± 14.0 years; 62.3% male), total cholesterol (TC) rose from 4.19 ± 0.87 mmol/L at baseline to 4.92, 5.03, and 5.21 mmol/L at the end of induction, 1 year, and 2 years (mixed-effects estimates +0.70 to +0.90; all P < .001). Low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) rose in parallel, and the LDL-C/HDL-C ratio did not increase. CRP reductions correlated with lipid rises (Spearman rho = −0.45 to −0.47; all P ≤ .02). No cardiovascular death, myocardial infarction, or stroke occurred (0/159); one venous thromboembolism and 3 hypertension cases were recorded. Conclusions: In patients with IBD treated with UPA, TC and LDL-C rose modestly alongside the resolution of inflammation; HDL-C improved and the LDL-C/HDL-C ratio did not increase. Lipid monitoring and individualized cardiovascular risk assessment are warranted during UPA therapy.